Furthermore, network pharmacology analysis revealed that BSKQF exerts its therapeutic effects on ADHD through multi-molecular, multi-target, and multi-pathway mechanisms, with NF-κB, an inflammation-related pathway, identified in the KEGG results. Here, NFKB1 is linked to attention deficit-hyperactivity disorder.